CytomX Therapeutics (NASDAQ:CTMX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.13), Fidelity Earnings reports. CytomX Therapeutics had a negative net margin of 158.05% and a negative return on equity of 77.05%. The business had revenue of $10.71 million during the quarter, compared to the consensus estimate of $23.58 million.
CTMX stock traded down $0.20 during midday trading on Friday, hitting $5.95. The stock had a trading volume of 538,700 shares, compared to its average volume of 437,329. CytomX Therapeutics has a 52 week low of $5.28 and a 52 week high of $19.75. The firm has a market capitalization of $281.99 million, a price-to-earnings ratio of -2.93 and a beta of 0.64. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 0.26. The stock has a 50-day simple moving average of $7.14 and a 200 day simple moving average of $9.47.
Several equities research analysts have recently weighed in on CTMX shares. Mizuho reissued a “buy” rating and issued a $16.00 price objective on shares of CytomX Therapeutics in a research report on Monday, August 12th. BidaskClub cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 1st. Zacks Investment Research cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Cowen reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Wednesday, August 7th. Finally, ValuEngine raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. CytomX Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $20.14.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Story: What is an economic bubble?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.